Fastest Growing Pharma & Biotech Companies in 2025, According to The Financial Times

The biopharma sector is sprinting into 2025 — not just with new molecules but with focused strategic execution.

The global pharmaceutical market size is projected to surpass $3 trillion by 2034, with the global biotech market size expected to hit over $5 trillion by 2034. Targeted therapies, AI-assisted pipelines and expanded access in chronic and rare diseases fuel this growth.

Beneath these big numbers, the industry is recalibrating.

Only 40% of US-listed biotechs had enough cash to last through 2025, according to EY, prompting a shift toward leaner pipelines, smarter capital deployment and faster clinical timelines.

Meanwhile, AI is becoming foundational, with up to 30% of new drug candidates expected to be AI-generated by year-end. In oncology, antibody-drug conjugates and individualized cancer vaccines are moving into late-stage trials, while GLP-1 therapies are changing how metabolic diseases are treated — and marketed.

The Financial Times recently ranked hundreds of fast-growing companies, including a standout group in the pharma and biotech sector.

From that list, we’ve selected 10 with direct involvement in drug development, therapeutic innovation or clinical advancement, whose growth stories reveal incredible traction.

And in today’s market, that traction translates. Read on to learn why the top 10 fastest growing pharma and biotech companies in 2025 are accelerating.

Evofem Biosciences (Absolute Growth: 3,984.8%)

San Diego-based Evofem is advancing hormone-free women’s health products. In late 2024, the company partnered with Windtree to reduce the production cost of its lead contraceptive gel Phexxi (lactic acid/citric acid/potassium bitartrate vaginal) by 60%. It also secured investor support for a merger with Aditxt’s subsidiary, Adifem, and raised $750,000 to bolster its near-term financial position.

Intra-Cellular Therapies (Absolute Growth: 1,951.3%)

This New York biotech focuses on central nervous system (CNS) disorders. In early 2025, Johnson & Johnson acquired the company for $14.6 billion, following the continued rise of antipsychotic drug Caplyta (lumateperone). The company is also developing ITI-1549, a non-hallucinogenic psychedelic targeting mood disorders through 5-HT2A receptor modulation without inducing cardiac or hallucinogenic effects.

BioCryst Pharmaceuticals (Absolute Growth: 1,760.6%)

Headquartered in North Carolina, BioCryst develops oral therapies for rare diseases. Its star oral drug, Orladeyo (berotralstat) for hereditary angioedema, brought $116.3 million in Q3 2024 revenue, driven by strong patient demand and international expansion. The company also launched a pivotal trial for a next-gen factor D inhibitor, aiming to treat complement-mediated disorders.

Marinus Pharmaceuticals (Absolute Growth: 1,703.8%)

Marinus, based in Pennsylvania, develops treatments for rare seizure disorders. In late 2024, Swedish rare disease company Immedica announced its plan to acquire Marinus for $151 million. The acquisition includes rights to Ztalmy (ganaxolone), an FDA-approved oral therapy for seizures associated with CDKL5 deficiency disorder. As a result, the deal added a US-based commercial asset to Immedica’s portfolio and set the stage for broader international expansion.

UroGen Pharma (Absolute Growth: 601%)

This Princeton-based company is developing non-surgical treatments for urothelial cancers. In March 2025, its Phase III ENVISION trial of UGN-102 for bladder cancer showed an 18-month duration of response of 80.6% in patients who achieved complete response at three months. The New Drug Application (NDA) for UGN-102 is also currently under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 13, 2025.

Xenetic Biosciences (Absolute Growth: 481.3%)

Xenetic is a Massachusetts-based oncology company developing DNase-based immunotherapies. In 2024, the company entered clinical trial service agreements to explore its DNase I platform for pancreatic and colorectal cancers in combination with chemotherapies and immunotherapies. In addition, Xenetic aims to file an Investigational Drug Application (IND) in 2025 and begin Phase I trials for difficult-to-treat solid tumors.

Nurix Therapeutics (Absolute Growth: 332%)

Based in San Francisco, Nurix is advancing protein modulation therapies for cancer and immune disorders. Its latest drug candidate, NX-0479, is set to enter clinical trials following FDA clearance. This marks progress in the company’s targeted protein degrader platform. Nurix also expanded its longstanding collaboration with Sanofi, now aiming to develop therapies targeting a novel E3 ligase.

Y-mAbs Therapeutics (Absolute Growth: 308.8%)

Y-mAbs, headquartered in New York, develops antibody-based therapies for pediatric cancers. The company also recently reorganized into two business units — Danyelza (naxitamab) and Radiopharmaceuticals — to streamline development and commercialization. Interim Phase II data presented at the Connective Tissue Oncology Society (CTOS) 2024 meeting showed a 60% disease control rate for naxitamab in second-line relapsed osteosarcoma.

JA Saúde Animal (Absolute Growth: 149.2%)

Based in São Paulo, JA Saúde Animal is a veterinary pharma company. In 2024, it partnered with FAZU and the Brazilian Association of Zebu Breeders. Together, they support the PNAT program, which evaluates young bulls for genetic traits linked to livestock productivity. The collaboration also aimed to strengthen JA’s role in advancing animal health and genetic innovation in Brazil’s agricultural sector.

Vertex Pharmaceuticals (Absolute Growth: 59.1%)

Boston-based Vertex remains a global leader in cystic fibrosis treatment. In 2025, the company advanced its cell therapy programs for type 1 diabetes, with investigational stem cell-derived islet therapies moving closer to clinical readiness. Additionally, longtime Vertex scientist Dr. Paul Negulescu was honored with the 2025 Canada Gairdner International Award for his contributions to cystic fibrosis drug discovery.

If you want your company to be featured on Xtalks.com, please email [email protected].